MYCN and prostate cancer: In 2011, Beltran and coworkers reported the frequent gene amplifications of MYCN and AURKA occurring in 40% of NEPC and 5% of prostate cancer adenocarcinomas, conferring a pronounced sensitivity of tumor cells to Aurora kinase inhibitors [680].